View Older Stories

May 21, 2026 04:39PM Bernstein SocGen Group Starts Incyte (INCY) at Market Perform

May 21, 2026 06:38AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Apr 29, 2026 10:15AM Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results

Apr 29, 2026 07:15AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Apr 28, 2026 04:32PM Incyte (INCY) PT Raised to $90 at Oppenheimer

Apr 28, 2026 03:10PM Incyte (INCY) PT Raised to $103 at Morgan Stanley

Apr 28, 2026 02:52PM Incyte (INCY) PT Raised to $124 at TD Cowen

Apr 28, 2026 07:06AM Incyte (INCY) Tops Q1 EPS by 46c; offers guidance

Apr 23, 2026 05:48AM MINJUVI approved in Australia for relapsed follicular lymphoma treatment

Apr 15, 2026 07:18AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Apr 2, 2026 07:01AM Adagene partners with Incyte for cancer drug combination study

Apr 2, 2026 05:07AM Incyte (INCY) Reiterated at Market Perform by Citizens- 'Shares are Fairly Valued'

Mar 30, 2026 10:19AM William Blair on Incyte (INCY): 'encouraged' by Ph3 data and deepened responses

Mar 30, 2026 07:42AM Incyte (INCY) Reiterated at Buy by Stifel on Constructive View for Povorcitinib

Mar 30, 2026 04:21AM Incyte reports 54-week data for hidradenitis suppurativa drug

Mar 25, 2026 09:13AM Incyte (INCY) PT Lowered to $94 at UBS

Mar 25, 2026 09:01AM Incyte names three executives to expanded leadership roles

Mar 25, 2026 06:57AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Mar 24, 2026 04:02PM Barclays reiterates Overweight on Incyte (INCY) despite mixed Ph3 trial results

Mar 16, 2026 12:51AM Jefferies Downgrades Incyte (INCY) to Hold

Mar 9, 2026 08:00AM Incyte (INCY) Reiterated at Buy by Stifel After FDA Response to sBLA Submission

Mar 6, 2026 04:42PM Incyte receives European approval for Zynyz anal cancer treatment

Feb 27, 2026 08:13AM CHMP recommends Eli Lilly's Olumiant for teens with severe hair loss

Feb 10, 2026 12:10PM Jefferies on Incyte (INCY): 'Growth Pipeline Remains Focuses'

Feb 10, 2026 09:28AM Truist on Incyte (INCY): 'Stock under pressure despite 4Q topline beat'

Feb 10, 2026 07:03AM Incyte (INCY) Misses Q4 EPS by 11c, Beats on Revenue

Feb 5, 2026 06:42AM H.C. Wainwright Starts Incyte (INCY) at Buy

Jan 30, 2026 09:29AM Incyte gets positive CHMP opinion for anal cancer drug Zynyz

Jan 20, 2026 05:36AM Wells Fargo Downgrades Incyte (INCY) to Equal Weight

Jan 13, 2026 08:50AM Incyte (INCY) PT Raised to $128 at TD Cowen

Jan 5, 2026 01:33PM Stifel Reiterates Buy Rating on Incyte (INCY)

Jan 5, 2026 12:10PM Incyte (INCY) PT Raised to $129 at Leerink Partners

Jan 5, 2026 07:30AM Incyte drug trial meets primary endpoint for lymphoma treatment

Dec 22, 2025 05:40AM Japan approves Incyte's Minjuvi for follicular lymphoma treatment

Dec 17, 2025 11:20AM INCYTE wins European approval for Minjuvi cancer treatment

Dec 11, 2025 05:59AM RBC Capital Reiterates Sector Perform Rating on Incyte (INCY)

Dec 9, 2025 05:12AM Incyte's (INCY) 989 is First-in-Class, Has Broad Clinical Utility - Citizens

Dec 8, 2025 04:30PM Incyte presents data showing 90% response rate for blood cancer drug

Dec 8, 2025 06:20AM Incyte (INCY) PT Raised to $128 at Leerink Partners

Dec 8, 2025 05:18AM Incyte (INCY) PT Raised to $118 at BofA Securities

Dec 8, 2025 04:53AM Mizuho Upgrades Incyte (INCY) to Outperform 'on Higher Confidence in Pipeline'

Dec 8, 2025 02:53AM FDA grants breakthrough therapy designation to INCA033989 for blood cancer

Dec 8, 2025 02:53AM Incyte reports phase 1 data for myelofibrosis drug INCA033989

Nov 17, 2025 03:57AM CHMP recommends Incyte's Minjuvi for relapsed follicular lymphoma

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 4, 2025 07:01AM Prelude Therapeutics secures $60M from Incyte option deal

Oct 29, 2025 09:59AM Incyte (INCY) PT Raised to $101 at TD Cowen; 'Q3 Beats Across All Franchises'

Oct 28, 2025 03:29PM Incyte (INCY) PT Raised to $84 at Oppenheimer

Oct 28, 2025 10:31AM Incyte (INCY) PT Raised to $109 at BofA Securities

Oct 28, 2025 07:02AM Incyte (INCY) Tops Q3 EPS by 67c; raises guidance

View Older Stories